Skip to content
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Neurology · POEMS Syndrome

Diagnosis and The POEMS Criteria

At a Glance

POEMS syndrome is diagnosed by finding both demyelinating polyneuropathy and a monoclonal plasma-cell disorder, at least one additional major feature such as high VEGF or sclerotic bone lesions, and at least one minor feature.

Because POEMS syndrome is so rare, reaching a definitive diagnosis requires a specific set of clinical “checkpoints.” Doctors around the world primarily use the Mayo Clinic/Dispenzieri criteria to confirm a diagnosis. This framework ensures that your symptoms are truly caused by POEMS and not a “lookalike” condition like CIDP or Multiple Myeloma [1][2].

The Mayo/Dispenzieri Diagnostic Framework

To be diagnosed with POEMS syndrome under this standard, you must meet a specific combination of major and minor criteria. Think of this as a “2 + 1 + 1” rule: you need the two mandatory major criteria, at least one other major criterion, and at least one minor criterion [2][3].

1. The Mandatory Major Criteria (Must have BOTH)

  • Polyneuropathy: This is the chronic nerve damage that usually brings patients to the doctor. In POEMS, it is typically “demyelinating,” meaning the protective coating of the nerves is being stripped away [4][5].
  • Monoclonal Plasma Cell Disorder: This is the “clone” of abnormal plasma cells. These cells produce a specific type of protein, known as an M-protein or paraprotein. In over 90% of POEMS cases, this protein is a lambda light chain [6][4].

2. Other Major Criteria (Must have at least ONE)

  • Sclerotic Bone Lesions: These are areas of the bone that have become abnormally dense or “hardened” (the opposite of the “holes” seen in other bone cancers) [7].
  • Castleman Disease: A rare disorder of the lymph nodes that sometimes occurs alongside POEMS [2].
  • Elevated VEGF: High levels of Vascular Endothelial Growth Factor in the blood [8].

3. Minor Criteria (Must have at least ONE)

  • Organomegaly: Enlargement of the liver, spleen, or lymph nodes [9].
  • Extravascular Volume Overload: Swelling (edema), fluid in the abdomen (ascites), or fluid around the lungs (pleural effusion) [7].
  • Endocrinopathy: Abnormalities in hormones (thyroid, adrenal, or reproductive). (Note: isolated diabetes or thyroid disease alone usually does not satisfy this criteria) [3].
  • Skin Changes: Hyperpigmentation (darkening), thickening, or increased hair growth [3].
  • Papilledema: Swelling of the optic nerve in the eye [10].
  • Thrombocytosis or Polycythemia: An abnormally high count of platelets or red blood cells [7].

The Japanese Diagnostic Criteria

In some medical settings, doctors may also reference the Japanese criteria, which require all three of the major features—polyneuropathy, the plasma cell clone, and elevated VEGF (specifically above 1,000 pg/mL in the serum)—plus at least two minor features [11][12]. The exact VEGF threshold depends on the assay and whether serum or plasma is used, and these criteria are meant to support—not replace—expert clinical diagnosis.

The Diagnostic Toolkit: Key Tests

Confirming these criteria requires several highly specialized tests. Because the abnormal “clone” in POEMS is often very small, standard tests can sometimes miss it [13].

Hunting the Clone: Immunofixation and Bone Marrow

A standard blood test called protein electrophoresis often fails to find the M-protein in POEMS because the levels are so low [14]. Instead, doctors use immunofixation (IFE) and serum free light chain tests, which are much more sensitive at “catching” the specific lambda light chain [5][15]. A serum free light chain test is also often run, though its results can sometimes be normal or difficult to interpret in POEMS (a negative free light chain test does not rule out the disease). A bone marrow biopsy is also used to identify the abnormal plasma cells directly. In many cases, careful marrow morphology and flow cytometry are needed [16][17].

Measuring the Fuel: The VEGF Test

VEGF is often called the “driver” of POEMS symptoms. A blood test for Vascular Endothelial Growth Factor is highly sensitive for POEMS, meaning it is elevated in the vast majority of active POEMS cases [18]. However, it is not 100% “specific”—meaning other things like iron deficiency, sleep apnea, or smoking can also raise VEGF levels. Your doctor must interpret your VEGF results in the context of your other symptoms [18][19].

Mapping the Bones: CT and PET Scans

Imaging is essential to find sclerotic bone lesions. Unlike the “lytic” (bone-eating) lesions seen in Multiple Myeloma that leave holes in the bone, POEMS lesions are osteosclerotic, meaning they are areas of abnormal, dense bone growth [20]. A standard “skeletal survey” (a series of X-rays) often misses these small lesions. Low-dose CT scans or PET/CT scans are commonly useful, with whole-body low-dose CT often preferred for sclerotic lesions, as PET imaging can sometimes miss lesions with low metabolic uptake [21][5].

Differentiating POEMS from “Lookalikes”

The reason these criteria are so specific is to distinguish POEMS from two other conditions it often mimics:

Feature POEMS Syndrome CIDP Multiple Myeloma
Nerve Damage Severe pain, demyelinating with early axonal loss [22] Can be painful, myelin loss [22] Sometimes present (from compression or kidney issues)
Bone Lesions Sclerotic (hard/dense) [20] None Lytic (soft/holes) [20]
Plasma Cell Clone Present (usually small) [13] Absent Present (usually large)
VEGF Levels Extremely high [18] Normal Usually normal

Understanding these distinctions is vital because the treatments for CIDP (like IVIG) generally do not work for POEMS, and the treatments for Multiple Myeloma must be adjusted to account for the unique systemic nature of POEMS [23][24]. Receiving a diagnosis that fits these specific criteria is the first step toward a treatment plan that actually targets the source of your symptoms.

Common questions in this guide

What findings are needed to diagnose POEMS syndrome?
The Mayo/Dispenzieri framework requires both demyelinating polyneuropathy and a monoclonal plasma-cell disorder. It also requires at least one other major finding, such as sclerotic bone lesions, Castleman disease, or high VEGF, plus at least one minor finding, such as organ enlargement, fluid buildup, hormone changes, skin changes, papilledema, or high blood counts.
Can normal protein electrophoresis or a normal free light chain result rule out POEMS?
No. The abnormal plasma-cell group in POEMS is often very small, so routine protein electrophoresis and sometimes the free light chain test may be normal. Immunofixation and a bone marrow examination can provide more sensitive evidence.
What does a high VEGF result mean in POEMS syndrome?
A high VEGF level is one of the major findings used to support POEMS and is common in active disease. It is not unique to POEMS because iron deficiency, sleep apnea, and smoking can also raise it, so doctors interpret the result with symptoms, imaging, and other tests.
Which scan is best for finding POEMS bone lesions?
Whole-body low-dose CT is often useful and may be preferred for finding the small sclerotic, or unusually dense, bone lesions associated with POEMS. A standard series of X-rays can miss them, and PET/CT may miss lesions that have low metabolic activity.
How can doctors tell POEMS apart from CIDP or multiple myeloma?
POEMS typically combines severe demyelinating neuropathy with a small plasma-cell clone, very high VEGF, and sclerotic bone lesions. CIDP does not have the plasma-cell clone or characteristic bone lesions, while multiple myeloma more often has a larger clone and lytic lesions, which create holes in bone. The distinction matters because treatments differ.
What is the difference between the Mayo and Japanese POEMS criteria?
The Mayo/Dispenzieri framework requires both polyneuropathy and a monoclonal plasma-cell disorder, plus at least one other major finding and one minor finding. The Japanese criteria require all three major features, including serum VEGF above 1,000 pg/mL, plus at least two minor features. The VEGF cutoff can depend on the test method, so an expert should apply the criteria.

Get notified when new evidence is published on Polyendocrine-polyneuropathy syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (24)
  1. 1

    POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management.

    Dispenzieri A

    American journal of hematology 2019; (94(7)):812-827 doi:10.1002/ajh.25495.

    PMID: 31012139
  2. 2

    POEMS syndrome: update on diagnosis, risk-stratification, and management.

    Dispenzieri A

    American journal of hematology 2015; (90(10)):951-62 doi:10.1002/ajh.24171.

    PMID: 26331353
  3. 3

    POEMS Syndrome: an Enigma.

    Warsame R, Yanamandra U, Kapoor P

    Current hematologic malignancy reports 2017; (12(2)):85-95 doi:10.1007/s11899-017-0367-0.

    PMID: 28299525
  4. 4

    POEMS syndrome: clinical update.

    Brown R, Ginsberg L

    Journal of neurology 2019; (266(1)):268-277 doi:10.1007/s00415-018-9110-6.

    PMID: 30498913
  5. 5

    Update on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome: A Review.

    Khouri J, Nakashima M, Wong S

    JAMA oncology 2021; (7(9)):1383-1391 doi:10.1001/jamaoncol.2021.0586.

    PMID: 34081097
  6. 6

    Neurological Peculiarities of POEMS Syndrome: Experience From a Brazilian University Center.

    Rosenstein RF, Soares Baima JP, Meneguin Pereira TD, et al.

    Muscle & nerve 2026; (73(3)):421-426 doi:10.1002/mus.70114.

    PMID: 41408967
  7. 7

    Polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS syndrome): a paraneoplastic syndrome.

    Kumar S, Sharma S

    Oxford medical case reports 2015; (2015(3)):237-40 doi:10.1093/omcr/omv023.

    PMID: 26634133
  8. 8

    POEMS syndrome: A multisystem clonal disorder.

    Ali T, Qazilbash MH

    European journal of haematology 2021; (106(1)):14-18 doi:10.1111/ejh.13514.

    PMID: 32889731
  9. 9

    POEMS syndrome: a rare cause of adrenal insufficiency in a young male.

    Prokop J, Estorninho J, Marote S, et al.

    Endocrinology, diabetes & metabolism case reports 2019; (2019()).

    PMID: 31967972
  10. 10

    POEMS syndrome: 2017 Update on diagnosis, risk stratification, and management.

    Dispenzieri A

    American journal of hematology 2017; (92(8)):814-829 doi:10.1002/ajh.24802.

    PMID: 28699668
  11. 11

    Proposal of new clinical diagnostic criteria for POEMS syndrome.

    Suichi T, Misawa S, Sato Y, et al.

    Journal of neurology, neurosurgery, and psychiatry 2019; (90(2)):133-137 doi:10.1136/jnnp-2018-318514.

    PMID: 30279213
  12. 12

    [Recent advances in pathogenesis, diagnosis, and therapeutic strategies for POEMS syndrome].

    Tsukamoto S

    [Rinsho ketsueki] The Japanese journal of clinical hematology 2026; (67(5)):453-461 doi:10.11406/rinketsu.67.453.

    PMID: 42236249
  13. 13

    POEMS Syndrome Without a Detectable Monoclonal Peak: The Critical Role of VEGF and Bone Marrow Biopsy in Diagnosis.

    J Pecorin P, A MM, Olson G, et al.

    Case reports in hematology 2025; (2025()):5530850 doi:10.1155/crh/5530850.

    PMID: 41018683
  14. 14

    POEMS Syndrome: Clinical and Laboratory Approach Towards Diagnosis.

    Mahto M, Kumar T, Kumar M, et al.

    Indian journal of clinical biochemistry : IJCB 2022; (37(3)):370-374 doi:10.1007/s12291-020-00940-3.

    PMID: 35873606
  15. 15

    POEMS syndrome with undetectable M-protein: a case report and literature review.

    Xue HY, Zhou L, Yuan QZ, et al.

    Diagnostic pathology 2024; (19(1)):74 doi:10.1186/s13000-024-01502-4.

    PMID: 38849857
  16. 16

    Detection of clonal plasma cells in POEMS syndrome using multiparameter flow cytometry.

    Ishii A, Tsukamoto S, Mimura N, et al.

    Scientific reports 2024; (14(1)):10362 doi:10.1038/s41598-024-61034-1.

    PMID: 38710832
  17. 17

    Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome.

    Bender S, Javaugue V, Saintamand A, et al.

    Blood 2020; (135(20)):1750-1758 doi:10.1182/blood.2019004197.

    PMID: 32243509
  18. 18

    Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome.

    Pihan M, Keddie S, D'Sa S, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2018; (5(5)):e486 doi:10.1212/NXI.0000000000000486.

    PMID: 30175160
  19. 19

    Requirement of Repeated Serum VEGF Measurements in POEMS Syndrome.

    Nomura T, Iwata I, Eguchi K, et al.

    Internal medicine (Tokyo, Japan) 2025; (64(5)):769-773 doi:10.2169/internalmedicine.4086-24.

    PMID: 39085069
  20. 20

    Diffuse large B-cell non-Hodgkin's lymphoma and osteosclerotic myeloma with features of POEMS syndrome.

    Ngamdu KS, Torabi A, Badri N, et al.

    Proceedings (Baylor University. Medical Center) 2016; (29(3)):306-8 doi:10.1080/08998280.2016.11929446.

    PMID: 27365880
  21. 21

    Bone lesions in Chinese POEMS syndrome patients: imaging characteristics and clinical implications.

    Wang F, Huang X, Zhang Y, et al.

    PeerJ 2016; (4()):e2294 doi:10.7717/peerj.2294.

    PMID: 27547585
  22. 22

    Clinical and electrophysiological profiles in early recognition of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes syndrome.

    Wang Q, Liu P, Ji LL, et al.

    Chinese medical journal 2019; (132(14)):1666-1672 doi:10.1097/CM9.0000000000000318.

    PMID: 31268911
  23. 23

    POEMS neuropathy: optimising diagnosis and management.

    Keddie S, D'Sa S, Foldes D, et al.

    Practical neurology 2018; (18(4)):278-290 doi:10.1136/practneurol-2017-001792.

    PMID: 29511110
  24. 24

    Thrombosis revealing POEMS syndrome. About a case.

    Dumas C, Bienvenu FH, Hicks J, et al.

    Annales de biologie clinique 2020; (78(2)):195-197 doi:10.1684/abc.2020.1534.

    PMID: 32162605

This page explains how POEMS syndrome is evaluated for informational purposes only and does not replace medical advice. A specialist should interpret your test results and apply the diagnostic criteria to your situation.